Loading market dashboard
Bristol-Myers Squibb Company
BMYHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.
What does this smart money investor see that the market is missing?
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Durability, not yield, is the deciding factor.
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.
Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front.
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.
Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory.
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.
Bristol Myers Squibb is mispriced as a melting ice cube, despite its Growth Portfolio surpassing Legacy revenues in Q1 2026. BMY's pipeline offers four near-term catalysts—including iberdomide, mezigdomide, milvexian, and Cobenfy—that could force a re-rating within seven months. Even using bearish consensus forecasts, BMY's DCF supports a $68.5/share valuation, about 20% above current levels, with downside well protected.
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma.
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.
Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs über verschiedene PD-L1-Expressionslevel und Subtypen hinweg vorgestellt werden; Daten untermauern das Potenzial von Pumitamig, einen neuen Behandlungsstandard in der Therapie von Lungenkrebs zu etablieren Pumitamig in Kombination mit Chemotherapie zeigte in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs bei beiden untersuchten Dosierungen eine robuste und konsistente Anti-Tumor-Aktivität mit höheren bestätigten objektiven Ansprechraten von 63,6 % bei nicht-plattenepithelialen und 72,7 % bei plattenepithelialen Subtypen bei der niedrigeren Dosierung Pumitamig wird im Rahmen eines umfassenden globalen klinischen Phase-3-Entwicklungsprogramms bei nicht-kleinzelligem Lungenkrebs weiterentwickelt, darunter der aktiv rekrutierende zulassungsrelevante Phase-3-Teil der ROSETTA Lung-02-Studie sowie zwei weitere globale klinische Phase-3-Studien MAINZ, Deutschland und PRINCETON, USA, 30.
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments.
Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.
Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos, and Reblozyl. Sales of this "trio" were $1.28 billion in Q1, up 42.2% year-over-year.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb faces a daunting patent cliff. The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.
The market appears to be short-sighted.
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.
The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
The stocks listed here yield between 3.8% and 7.4%. Their valuations are incredibly low when compared to the S&P 500.
Rose's Income Garden portfolio targets high-yield, quality dividend stocks across 10 sectors, emphasizing value and credit quality. Current high-yield sector picks include MO, BMY, AES, VZ, GPC, and VICI, each with yields above 4.5% and favorable valuation or growth profiles. RIG's forward yield exceeds 6.09%, with YTD performance at 8.39%, outpacing SPY's 0.99% yield and focusing on undervalued dividend payers.
Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next blockbusters.
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical pl.
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter to stockholders in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.
On May 12, 2026, we delve into the DCF analysis for Bristol-Myers Squibb Co (BMY), a company currently trading at $55.67. The stock has experienced a mixed perf
U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long ‑ term growth SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.
China's Jiangsu Hengrui Pharmaceuticals said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to develop 13 early‑stage oncology, hematology and immunology programmes, with potential milestone payments of up to $15.2 billion.
Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company's portfolio of newer drugs, along with its deep pipeline, can help it overcome this headwind.
Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.
Bristol Myers Squibb faces a major patent cliff but is well-equipped with a robust pipeline and significant CAR-T optionality. BMY trades at a discounted 9.4x forward P/E, reflecting patent cliff fears, yet offers 15-20% base case upside plus a 4.3% dividend yield. The 2026 catalyst stack includes Milvexian, Iberdomide, Cobenfy, and Sotyktu, any of which could drive a rerating to 10x-11x forward P/E.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
It scored crushing beats on both revenue and profitability in its first quarter.
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
Bristol-Myers Squibb Co. (NYSE:BMY) shares are up on Thursday as the company reported its first-quarter financial results for 2026.
Bristol-Myers beats Q1 estimates as strong Growth Portfolio sales and Eliquis demand offset legacy drug declines.
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.8 per share a year ago.
Q1 2026 revenue was $11.49 billion. The estimated revenue was $10.91 billion.GAAP EPS was $1.31. The estimated EPS was $1.19.Non-GAAP EPS was $1.58. The estima
GOOG sees results from AI investments, Fed meeting reveals growing divisions, and more
